Edgewell Personal Care Divests Feminine Care Unit for $340M, Tightens Strategic Focus

Edgewell pares portfolio with sale of Feminine Care unit

SHELTON, Conn. — Edgewell Personal Care Company completes the divestiture of its Feminine Care business for $340 million, a move the company says sharpens its portfolio and strengthens its balance sheet as it presses ahead with a corporate transformation. Management frames the transaction as a step to create a more focused, agile consumer products company that can concentrate resources on core categories such as shaving and skin care.

The company presents most metrics on a continuing‑operations basis that exclude the divested business, while also providing consolidated figures to allow comparison with prior guidance issued on a consolidated basis. Edgewell estimates the annualized impact of the sale is favorable to its previous outlook, and management says the simplified structure better positions the company to execute cost and growth initiatives tied to its transformation plan.

Chief Executive Rod Little says the streamlined business model allows Edgewell to redeploy management attention and capital, and to pursue sustainable growth opportunities more efficiently. The company signals that the transaction supports its stated aims to enhance operational agility, though it does not specify immediate uses of proceeds beyond strengthening the balance sheet. Edgewell accompanies the release with reconciliations of non‑GAAP measures to the most directly comparable GAAP figures.

Quarterly snapshot

For the quarter ended Dec. 31, 2025, Edgewell reports consolidated net sales of $486.8 million, up 1.8% year‑over‑year; organic net sales, which exclude currency movements and are adjusted for the divestiture, decline 0.3%. On a GAAP basis the company reports a diluted net loss per share of $1.41, compared with a $0.04 loss a year earlier, while adjusted earnings per share come in at $0.03 versus $0.07 in the prior‑year quarter. Management says results modestly exceed expectations for sales, adjusted EPS and adjusted EBITDA.

Outlook and reporting

Edgewell reiterates that, following the transaction and related adjustments, its full‑year outlook for continuing operations remains consistent with prior guidance for sales, adjusted EPS, adjusted EBITDA and free cash flow. The company notes first‑quarter guidance had been provided on a consolidated basis inclusive of the Feminine Care business, and says investors should reference the reconciliations supplied with the Feb. 9, 2026 release for detail.